Nicotinic acid

DRUG17 trials

Sponsors

Heidelberg University, Craigavon Area Hospital, Palo Alto Medical Foundation, Medical University of Vienna, University Hospital, Toulouse

Conditions

AtherosclerosisBranch Retinal Vein OcclusionCentral Retinal Vein OcclusionCoronary ArteriosclerosisDiabetes Mellitus Type 2Diabetes Mellitus, Type 2DyslipidemiaDyslipidemias

Phase 1

Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression

Heidelberg UniversityHealthy

Target: 18Updated: 2006-03-15

Phase 2

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

CompletedNCT00493064

Palo Alto Medical FoundationRetinal Vein Occlusion

Start: 2006-10-31End: 2016-10-31Updated: 2018-12-21

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

TerminatedNCT00500045

Palo Alto Medical FoundationBranch Retinal Vein Occlusion, Central Retinal Vein Occlusion

Start: 2007-02-28End: 2016-10-31Updated: 2019-11-13

Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects

CompletedNCT01083329

University Hospital, ToulouseObesity

Start: 2010-01-31End: 2012-06-30Updated: 2020-07-29

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

CompletedNCT02890992

SanofiHypercholesterolaemia

Start: 2016-09-15End: 2019-02-22Updated: 2019-09-06

Regulation of Endogenous Glucose Production by Central KATP Channels

RecruitingNCT03540758

Meredith HawkinsGlucose, High Blood, Glucose Metabolism Disorders, Type 2 Diabetes Mellitus

Start: 2018-08-01End: 2027-04-30Target: 100Updated: 2025-04-01

The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

WithdrawnNCT03685773

Albert Einstein College of MedicineDiabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders

Start: 2019-04-21End: 2023-04-21Updated: 2023-06-05

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

RecruitingNCT06991712

Christopher Kai Shun LeungGlaucoma

Start: 2025-05-19End: 2026-12-31Target: 138Updated: 2025-06-26

Phase 3

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

CompletedNCT03510884

SanofiHypercholesterolaemia

Start: 2018-05-31End: 2022-08-05Updated: 2023-05-06

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

CompletedNCT03510715

SanofiHypercholesterolemia

Start: 2018-08-31End: 2020-02-17Updated: 2020-12-29

Phase 4

The Low HDL On Six Weeks Statin Therapy (LOW) Study

Craigavon Area HospitalCoronary Arteriosclerosis, HDL Cholesterol, Lipoproteins

Start: 2005-11-30Target: 60Updated: 2006-09-13

Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)

Medical University of ViennaAtherosclerosis, Dyslipidemia

Start: 2008-06-30Target: 200Updated: 2011-07-22

Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL

TerminatedNCT01450410

Xavier Pinto SalaDyslipidemias

Start: 2012-07-31End: 2013-05-31Updated: 2013-01-29

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

CompletedNCT02642159

SanofiDyslipidemia

Start: 2016-03-15End: 2017-05-15Updated: 2018-05-01

Unknown Phase

Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism

CompletedNCT01803594

University of California, DavisDyslipidemia

Start: 2012-08-31End: 2015-03-13Updated: 2022-09-30

Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)

CompletedNCT02808182

Université de SherbrookeImpaired Glucose Tolerance

Start: 2017-01-17End: 2021-05-31Updated: 2025-01-27

Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery

RecruitingNCT05934409

Université de SherbrookeDiabetes Mellitus Type 2

Start: 2023-11-01End: 2028-05-01Target: 40Updated: 2026-02-10

Related Papers

Nicotinic acid increases adipose tissue dietary fatty acid trapping and reduces postprandial hepatic and cardiac fatty acid uptake in prediabetes

European Journal of Pharmacology2025-03-291 citations

Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

JAMA Pediatrics2024-02-0524 citations

Adipocyte hypertrophy associates with <i>in vivo</i> postprandial fatty acid metabolism and adipose single-cell transcriptional dynamics.

2023-12-089 citations

Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study

Arteriosclerosis Thrombosis and Vascular Biology2022-11-0337 citations

Total Postprandial Hepatic Nonesterified and Dietary Fatty Acid Uptake Is Increased and Insufficiently Curbed by Adipose Tissue Fatty Acid Trapping in Prediabetes With Overweight

Diabetes2022-06-2418 citations

Increased postprandial nonesterified fatty acid efflux from adipose tissue in prediabetes is offset by enhanced dietary fatty acid adipose trapping.

2021-04-1920 citations

PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.

2020-03-2836 citations

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Cardiovascular Diabetology2020-02-0831 citations

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.

2019-11-0926 citations

Niacin induces miR-502-3p expression which impairs insulin sensitivity in human adipocytes.

2018-11-2715 citations

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

2018-03-2364 citations

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

2017-05-2517 citations